TRGV9 and cancer: Significant heterogeneity was observed between the three molecular subtypes in cancer-related signaling pathways, including T cell co-stimulation-induced inflammation-promoting pathways, MYC targets v1, MYC targets v2, the G2M checkpoint, and E2F.